BridgeBio Pharma (2CL) AI Stock Analysis

Company Guidance

Management said Attruby is tracking to meet or beat its $4 billion peak year sales assumption, with $4 billion in peak year sales across the other 3 brands, and that $25 million to $30 million is the right number near term for sequential revenue growth, with the number eventually going up more from there. The company expects 3 launches in the next 7 months: BBP-418 on November 27, infigratinib on February 4, 2027, and encaleret on May 8, 2027; it expects to reach at least 90% of MDA centers by PDUFA for BBP-418, fully penetrate the 500 identified patient pool by year 3, submit an MAA for BBP-418 in the first half of 2028, and submit top-line FORTIFY month 36 results in late '27 or early '28. Management anticipates OpEx will catch up in the fourth quarter of this year, followed by a more modest steady growth paired with improvement of the operating line throughout 2027 and beyond; it expects to average an operating loss of around $90 million to $100 million a quarter this year versus about $130 million loss a quarter last year, move towards a breakeven point throughout 2027, and reach 2028 where all 4 of the brands have a chance to be profitable on a stand-alone basis. RECLAIM-HP will enroll approximately 160 individuals, with top line results anticipated in the next 15 months.